China Prescription Drug 2007 Issue 11 Signal Mining and Evaluation in Pharmacovigilance

Signal Mining and Evaluation in Pharmacovigilance
chen yi xin

..............page:53-56

Vigilance is More Important than Monitoring
sun zhong shi

..............page:57-59

jiang xue zhi yao shi chang , xiao fei gui mo kuo zhang 2006 nian jiang xue zhi yao ji zhong tong yong ming pin zhong shi chang fen xi
liu ning

..............page:78-79

jian ben san fen zhi liao yun 20 zhou qian xian zhao liu chan
du bi jun ; zhang jian ping

..............page:80-81

fu fang gan cao suan zuo lian he wai yong 2% mi nuo di er rong ye zhi liao ban tu 120 li liao xiao guan cha
huang mei he

..............page:81

zhi liao gu sui zeng sheng yi chang zong he zheng de xin yao di xi ta bin (decitabine) zhu she ye
cao lei ; liang ke ; zhang hao ; zhu er jia ; tan zai you

..............page:82-83

zhi jie gao su ren jia a !
yang tian

..............page:2

gai nian de lv xian yin ru zhe
zuo xue mei

..............page:34

su lan

..............page:69,77

Learning from FDA's Experience on Reevaluating of Launched Drugs
yu li

..............page:50-52

A Glimpse of Pharmaceutical Industry in China in 2007 and the Development Forecast in the Coming 2008
tan yong

..............page:84

The Survival Machines of The Selfish Gene——In You and Me
tai zuo

..............page:48-49

Clinical Decision-making and Evidence-based Medicine
wei jing fa

..............page:46-47

adr feng xiang biao

..............page:20-21

xin yao gong gao lan

..............page:18-19

From Backstage to Proscenium——the 1st Clinical Pain Symposium of China
yu li

..............page:16-17

Pharmacoeconomics in China——A More Pressing Need than in Developed Countries
pan li

..............page:14-15

xin shi / sheng yin shu zi

..............page:10-13

Lenalidomide - The Phoenix Rises
alan f.list; qiu yu

..............page:9

Keeping Vigilant about Drug Safety
dan jones; yin hui juan

..............page:8

HDL - Is It Still a Viable Therapeutic Target?
daniel j. rader; hai yan

..............page:7

lai xin

..............page:5-6

ming kan

..............page:3

Progress and Development in Diagnosis and Treatment of Hodgkin's Lymphoma
jiang wen qi

..............page:73-76

Progress and Development in the Treatment of Relapsing Metastatic Colon and Rectal Carcinomas
li jin

..............page:70-73

Development in the Treatment of Hepatic Encephalopathy
fan zhu ping ; wu liu

..............page:67-68

Therapeutic Therapy for Portal Hypertension due to Cirrhosis
lu lun gen

..............page:65-66

Clinical Studies of Ascites due to Cirrhosis
qiu de kai

..............page:60-64

From Annotation to Blueprint——Drug Withdrawal System in U.S.A. And its Enlightenment
zhang zuo zuo ; guo chun zhen

..............page:43-45

Power Source, Cost-benefit, and Responsibility Undertaking in Drug Withdrawal
fu wei gang

..............page:41-42

Political Analysis of Drug Withdrawal System
liu peng

..............page:39-40

Roche Formally Opened its Pharma Development Center in China (PDCC)——Beginning of More Miracles
mao dong lei

..............page:24-26

Dr Rae Yuan, Head of Roche's Pharma Development Centre in China
mao dong lei

..............page:27

An Interview to Dr. Jean-Jacques Garaud, Head of Global Pharma Development at Roche
zuo xue mei

..............page:28

The Century Turn of Roche——A Story of Giant Pharm
huang dong lin

..............page:29-31

Central Laboratory——An Industry with Annual Output Value Surpassing 1 Billion USD
zuo xue mei

..............page:32-34

Wyeth Stepping Up Alzheimer's Effort
zuo xue mei

..............page:36-37

Drug Withdrawal System in Venture Society
song hua lin

..............page:38

The Important Role of China
mao dong lei

..............page:22

R& D Centers in China——Transfer of Drug R&D to China
zuo xue mei

..............page:23